Dr. Katherine Gallagher
Post - Doc
Collaborations
Videos
Bio
Kate completed an MRC(UK)-funded PhD at the London School of Hygiene & Tropical Medicine in 2016 that included studies to assess whether human papillomavirus (HPV) infection increased HIV acquisition in East African women, to evaluate HPV vaccine introduction in Tanzania and to collate 'lessons learnt' during HPV vaccine introduction in 46 low and middle-income countries. Whilst based at the Mwanza Intervention Trials Unit in Tanzania for 2014 and 2015, she also aided the initial set-up of the EBOVAC1 Ebola vaccine Phase 1 trial. As a post-doc, she worked as the London-based academic coordinator of the EBOVAC1 projects including two large phase 2b vaccine trials in Sierra Leone and 2 nested observational studies. Since July 2018 Kate has been based at the KEMRI-Wellcome Trust Research Programme in Kilifi, Kenya, leading an individually randomised trial to assess whether lower/ fractional doses of the two currently available pneumococcal conjugate vaccines (PCV) protect Kenyan infants as well as the full dose schedules. We are also collaborating with Epicentre to complete a cluster randomised controlled trial of fractional dose PCV in Niger. The results could be used to enable countries unable to afford the full cost of the vaccine, to continue delivering it in the childhood immunisation programme in the absence of Gavi support and/or to perform fractional dose mass campaigns in settings with low routine coverage.
See moreCurrent Work
Kate’s areas of interest are infectious disease epidemiology and vaccine research. She is currently co-supervising a PhD student who will estimate the burden of pneumococcal disease in Ethiopia using carriage surveys. During the COVID-19 pandemic Kate collaborated with colleagues at KWTRP to conduct sero-surveillance and a household study of SARS-CoV-2 transmission. She also collaborated with colleagues in the Democratic Republic of the Congo, Sierra Leone and Uganda to assess the impact of lockdowns on the provision and utilisation of routine primary healthcare services.
Collaborations; Ifedayo Adetifa (CDC Nigeria), Christian Bottomley, Deborah Watson-Jones (London School of Hygiene & Tropical Medicine), David Goldblatt (University College London), Bailah Leigh (University of Sierra Leone), Hugo Kavunga (Institut National Research Biomedical, Goma), Eugene Ruzagira (Uganda Virus Research Institute), Rebecca Grais (Epicentre), Yadeta Dessie (Haramaya University)
Other roles;
MSc Supervision: 5 past MSc students (2 at KWTRP, 3 at LSHTM)
Current Co-Supervisor of PhD: Hiwot Yigsaw (Haramaya University)
PhD Advisory Board: Aishatu Adamu, Deus Thindwa
Other roles:
Module organiser for the Study Design module, Distance Learning Epidemiology Programme, London School of Hygiene & Tropical Medicine
Recent publications
Fractional Doses of Pneumococcal Conjugate Vaccine - A Noninferiority Trial.
Gallagher, K. E., Lucinde, R., Bottomley, C., Kaniu, M., Suaad, B., Mutahi, M., Mwalekwa, L., Ragab, S., Twi-Yeboah, L., Berkley, J. A., Hamaluba, M., Karani, A., Shangala, J., Otiende, M., Gardiner, E., Mugo, D., Smith, P. G., Tabu, C., Were, F., Goldblatt, D., Scott, J. A. G.
N Engl J Med, (2024). :
Factors predicting mortality in hospitalised HIV-negative children with lower-chest-wall indrawing pneumonia and implications for management.
Gallagher, K. E., Awori, J. O., Knoll, M. D., Rhodes, J., Higdon, M. M., Hammitt, L. L., Prosperi, C., Baggett, H. C., Brooks, W. A., Fancourt, N., Feikin, D. R., Howie, S. R. C., Kotloff, K. L., Tapia, M. D., Levine, O. S., Madhi, S. A., Murdoch, D. R., O'Brien, K. L., Thea, D. M., Baillie, V. L., Ebruke, B. E., Kamau, A., Moore, D. P., Mwananyanda, L., Olutunde, E. O., Seidenberg, P., Sow, S. O., Thamthitiwat, S., Scott, J. A. G.
PLoS One, (2024). 19:e0297159
SARS-CoV-2 seroprevalence and implications for population immunity: Evidence from two Health and Demographic Surveillance System sites in Kenya, February-December 2022.
Kagucia, E. W., Ziraba, A. K., Nyagwange, J., Kutima, B., Kimani, M., Akech, D., Ng'oda, M., Sigilai, A., Mugo, D., Karanja, H., Gitonga, J., Karani, A., Toroitich, M., Karia, B., Otiende, M., Njeri, A., Aman, R., Amoth, P., Mwangangi, M., Kasera, K., Ng'ang'a, W., Voller, S., Ochola-Oyier, L. I., Bottomley, C., Nyaguara, A., Munywoki, P. K., Bigogo, G., Maitha, E., Uyoga, S., Gallagher, K. E., Etyang, A. O., Barasa, E., Mwangangi, J., Bejon, P., Adetifa, I. M. O., Warimwe, G. M., Scott, J. A. G., Agweyu, A.
Influenza Other Respir Viruses, (2023). 17:e13173
Symptom prevalence and secondary attack rate of SARS-CoV-2 in rural Kenyan households: A prospective cohort study.
Gallagher, K. E., Nyiro, J., Agoti, C. N., Maitha, E., Nyagwange, J., Karani, A., Bottomley, C., Murunga, N., Githinji, G., Mutunga, M., Ochola-Oyier, L. I., Kombe, I., Nyaguara, A., Kagucia, E. W., Warimwe, G., Agweyu, A., Tsofa, B., Bejon, P., Scott, J. A. G., Nokes, D. J.
Influenza Other Respir Viruses, (2023). 17:e13185
Population immunity to pneumococcal serotypes in Kilifi, Kenya, before and 6 years after the introduction of PCV10 with a catch-up campaign: an observational study of cross-sectional serosurveys.
Gallagher, K. E., Adetifa, I. M. O., Mburu, C., Bottomley, C., Akech, D., Karani, A., Pearce, E., Wang, Y., Kagucia, E. W., Goldblatt, D., Hammitt, L. L., Scott, J. A. G.
Lancet Infect Dis, (2023). S1473-3099:00206-2
Dr. Katherine Gallagher
Post - Doc
Biography
Kate completed an MRC(UK)-funded PhD at the London School of Hygiene & Tropical Medicine in 2016 that included studies to assess whether human papillomavirus (HPV) infection increased HIV acquisition in East African women, to evaluate HPV vaccine introduction in Tanzania and to collate 'lessons learnt' during HPV vaccine introduction in 46 low and middle-income countries. Whilst based at the Mwanza Intervention Trials Unit in Tanzania for 2014 and 2015, she also aided the initial set-up of the EBOVAC1 Ebola vaccine Phase 1 trial. As a post-doc, she worked as the London-based academic coordinator of the EBOVAC1 projects including two large phase 2b vaccine trials in Sierra Leone and 2 nested observational studies. Since July 2018 Kate has been based at the KEMRI-Wellcome Trust Research Programme in Kilifi, Kenya, leading an individually randomised trial to assess whether lower/ fractional doses of the two currently available pneumococcal conjugate vaccines (PCV) protect Kenyan infants as well as the full dose schedules. We are also collaborating with Epicentre to complete a cluster randomised controlled trial of fractional dose PCV in Niger. The results could be used to enable countries unable to afford the full cost of the vaccine, to continue delivering it in the childhood immunisation programme in the absence of Gavi support and/or to perform fractional dose mass campaigns in settings with low routine coverage.
See moreCurrent Work
Kate’s areas of interest are infectious disease epidemiology and vaccine research. She is currently co-supervising a PhD student who will estimate the burden of pneumococcal disease in Ethiopia using carriage surveys. During the COVID-19 pandemic Kate collaborated with colleagues at KWTRP to conduct sero-surveillance and a household study of SARS-CoV-2 transmission. She also collaborated with colleagues in the Democratic Republic of the Congo, Sierra Leone and Uganda to assess the impact of lockdowns on the provision and utilisation of routine primary healthcare services.
Collaborations; Ifedayo Adetifa (CDC Nigeria), Christian Bottomley, Deborah Watson-Jones (London School of Hygiene & Tropical Medicine), David Goldblatt (University College London), Bailah Leigh (University of Sierra Leone), Hugo Kavunga (Institut National Research Biomedical, Goma), Eugene Ruzagira (Uganda Virus Research Institute), Rebecca Grais (Epicentre), Yadeta Dessie (Haramaya University)
Other roles;
MSc Supervision: 5 past MSc students (2 at KWTRP, 3 at LSHTM)
Current Co-Supervisor of PhD: Hiwot Yigsaw (Haramaya University)
PhD Advisory Board: Aishatu Adamu, Deus Thindwa
Other roles:
Module organiser for the Study Design module, Distance Learning Epidemiology Programme, London School of Hygiene & Tropical Medicine
Collaborations
Project Research
No active details yet
Videos
Fractional Doses of Pneumococcal Conjugate Vaccine - A Noninferiority Trial.
Gallagher, K. E., Lucinde, R., Bottomley, C., Kaniu, M., Suaad, B., Mutahi, M., Mwalekwa, L., Ragab, S., Twi-Yeboah, L., Berkley, J. A., Hamaluba, M., Karani, A., Shangala, J., Otiende, M., Gardiner, E., Mugo, D., Smith, P. G., Tabu, C., Were, F., Goldblatt, D., Scott, J. A. G.
N Engl J Med, (2024). :
Factors predicting mortality in hospitalised HIV-negative children with lower-chest-wall indrawing pneumonia and implications for management.
Gallagher, K. E., Awori, J. O., Knoll, M. D., Rhodes, J., Higdon, M. M., Hammitt, L. L., Prosperi, C., Baggett, H. C., Brooks, W. A., Fancourt, N., Feikin, D. R., Howie, S. R. C., Kotloff, K. L., Tapia, M. D., Levine, O. S., Madhi, S. A., Murdoch, D. R., O'Brien, K. L., Thea, D. M., Baillie, V. L., Ebruke, B. E., Kamau, A., Moore, D. P., Mwananyanda, L., Olutunde, E. O., Seidenberg, P., Sow, S. O., Thamthitiwat, S., Scott, J. A. G.
PLoS One, (2024). 19:e0297159
SARS-CoV-2 seroprevalence and implications for population immunity: Evidence from two Health and Demographic Surveillance System sites in Kenya, February-December 2022.
Kagucia, E. W., Ziraba, A. K., Nyagwange, J., Kutima, B., Kimani, M., Akech, D., Ng'oda, M., Sigilai, A., Mugo, D., Karanja, H., Gitonga, J., Karani, A., Toroitich, M., Karia, B., Otiende, M., Njeri, A., Aman, R., Amoth, P., Mwangangi, M., Kasera, K., Ng'ang'a, W., Voller, S., Ochola-Oyier, L. I., Bottomley, C., Nyaguara, A., Munywoki, P. K., Bigogo, G., Maitha, E., Uyoga, S., Gallagher, K. E., Etyang, A. O., Barasa, E., Mwangangi, J., Bejon, P., Adetifa, I. M. O., Warimwe, G. M., Scott, J. A. G., Agweyu, A.
Influenza Other Respir Viruses, (2023). 17:e13173
Symptom prevalence and secondary attack rate of SARS-CoV-2 in rural Kenyan households: A prospective cohort study.
Gallagher, K. E., Nyiro, J., Agoti, C. N., Maitha, E., Nyagwange, J., Karani, A., Bottomley, C., Murunga, N., Githinji, G., Mutunga, M., Ochola-Oyier, L. I., Kombe, I., Nyaguara, A., Kagucia, E. W., Warimwe, G., Agweyu, A., Tsofa, B., Bejon, P., Scott, J. A. G., Nokes, D. J.
Influenza Other Respir Viruses, (2023). 17:e13185
Population immunity to pneumococcal serotypes in Kilifi, Kenya, before and 6 years after the introduction of PCV10 with a catch-up campaign: an observational study of cross-sectional serosurveys.
Gallagher, K. E., Adetifa, I. M. O., Mburu, C., Bottomley, C., Akech, D., Karani, A., Pearce, E., Wang, Y., Kagucia, E. W., Goldblatt, D., Hammitt, L. L., Scott, J. A. G.
Lancet Infect Dis, (2023). S1473-3099:00206-2
Dr. Katherine Gallagher 9
Post - Doc
Biography
Kate completed an MRC(UK)-funded PhD at the London School of Hygiene & Tropical Medicine in 2016 that included studies to assess whether human papillomavirus (HPV) infection increased HIV acquisition in East African women, to evaluate HPV vaccine introduction in Tanzania and to collate 'lessons learnt' during HPV vaccine introduction in 46 low and middle-income countries. Whilst based at the Mwanza Intervention Trials Unit in Tanzania for 2014 and 2015, she also aided the initial set-up of the EBOVAC1 Ebola vaccine Phase 1 trial. As a post-doc, she worked as the London-based academic coordinator of the EBOVAC1 projects including two large phase 2b vaccine trials in Sierra Leone and 2 nested observational studies. Since July 2018 Kate has been based at the KEMRI-Wellcome Trust Research Programme in Kilifi, Kenya, leading an individually randomised trial to assess whether lower/ fractional doses of the two currently available pneumococcal conjugate vaccines (PCV) protect Kenyan infants as well as the full dose schedules. We are also collaborating with Epicentre to complete a cluster randomised controlled trial of fractional dose PCV in Niger. The results could be used to enable countries unable to afford the full cost of the vaccine, to continue delivering it in the childhood immunisation programme in the absence of Gavi support and/or to perform fractional dose mass campaigns in settings with low routine coverage.